QUINUPRAMINE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H24N2
Molecular Weight	304.4287
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C1CN2CCC1C(C2)N3C4=CC=CC=C4CCC5=CC=CC=C35

InChI

InChIKey=JCBQCKFFSPGEDY-UHFFFAOYSA-N

InChI=1S/C21H24N2/c1-3-7-19-16(5-1)9-10-17-6-2-4-8-20(17)23(19)21-15-22-13-11-18(21)12-14-22/h1-8,18,21H,9-15H2

HIDE SMILES / InChI

Molecular Formula	C21H24N2
Molecular Weight	304.4287
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16644151 | https://www.ncbi.nlm.nih.gov/pubmed/2613103 | (1984) The Japanese Journal of Pharmacology, page 458, retrieved from: https://books.google.ru/books?id=1UfYAAAAIAAJ

Quinupramine is a tricyclic antidepressant used in the treatment of reactive and endogenous depression. Quinupramine was found to possess a higher affinity for muscarinic cholinergic receptor binding sites in brain and heart, compared with imipramine. Quinupramine also displayed a substantial affinity for 5-HT2 receptors in the cerebral cortex. Quinupramine may show many adverse side effects such as dry mouth, urinary retention, and daytime drowsiness.

Approval Year

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
Enhanced transdermal controlled delivery of glimepiride from the ethylene-vinyl acetate matrix.	2009-08	19606946
Development and biopharmaceutical evaluation of quinupramine-EVA matrix containing penetration enhancer for the enhanced transdermal absorption in rats.	2007	17963142
Physicochemical characteristics of quinupramine in the EVA matrix.	2006-08-31	16844330
Release characteristics of quinupramine from the ethylene-vinyl acetate matrix.	2006-06-06	16644151
Rapid high-performance liquid chromatographic measurement of buspirone in human plasma after overdose.	2004-11	15386505
[Behavioral effects of quinupramine, a new tricyclic antidepressant].	1988-06	3417209

Sample Use Guides

In Vivo Use Guide

5–15 mg daily dose

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:49:42 GMT 2025` Edited by `admin` on `Mon Mar 31 18:49:42 GMT 2025`
Record UNII	29O61HFF4L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

QUINUPRAMINE

Official Name

English

QUINUPRAMINE [MI]

Preferred Name

English

QUINUPRAMINE [MART.]

Common Name

English

Quinupramine [WHO-DD]

Common Name

English

quinupramine [INN]

Common Name

English

10,11-DIHYDRO-5-(3-QUINUCLIDINYL)-5H-DIBENZ(B,F)AZEPINE

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

N06AA23